Figma's Q2 2025 Earnings: Strong Revenue Growth Meets Market Skepticism
Figma's first public earnings report for Q2 2025 shows revenue beat expectations, but stock plunges after profit came in below estimates and amidst AI monetization concerns.
Figma's first public earnings report for Q2 2025 shows revenue beat expectations, but stock plunges after profit came in below estimates and amidst AI monetization concerns.
Beam Therapeutics rallied after Wave Life Sciences' WVE-006 trial data for alpha-1 antitrypsin deficiency (AATD) fell below expectations.
FDA accepted cytisinicline NDA for smoking cessation, with a PDUFA date of June 20, 2026. This marks a significant step, potentially offering the first new FDA-approved therapy in two decades to combat nicotine dependence, supported by strong clinical data and safety.
Macy's reports its first same-store sales growth in 12 quarters, beats Q2 earnings expectations, and raises full-year guidance, signaling its turnaround strategy is gaining traction.
TVA, ENTRA1, & NuScale partner for 6 GW SMR nuclear expansion to power 4.5M homes or 60 data centers. This public-private initiative boosts energy security, meets soaring demand from AI/tech, and validates NuScale's SMR technology.
Judge upheld Google's $20B Apple search deal, avoiding Chrome sale. Google must share search data & end exclusive contracts, a win for both boosting shares. Paves way for AI collaboration, but DOJ weighing options.